Oxford BioDynamics wins approval for £9.15M placing, tripling its share count
What's the deal? Oxford BioDynamicsDealroom has a profile for this one. Try Dealroom → has secured shareholder approval to admit 9,150,000,000 new ordinary shares to London's AIM, completing a £9.15 million placing first announced on August 10, 2026. Shareholders backed all resolutions at a General Meeting on August 26, with trading in the new shares due to begin at 8:00 BST on August 27.
Who's putting in money? Five directors and senior executives took part at £0.001 per share. Non-executive director Martin Diggle, via the Vulpes Life Sciences Fund and Vulpes Testudo Fund, subscribed for 500,000,000 shares, lifting his holding to 8.32% of the enlarged capital.
Chief executive officer Richard Compton bought 300,000,000 shares for a 2.2% stake. Non-executive chairman Iain Ross, chief scientific officer Alexandre Akoulitchev, and chief financial officer Paul Stockdale also participated.
What's the endgame? Oxford BioDynamics is an Oxford-based biotechnology company building precision clinical diagnostic tests. Its EpiSwitch Orion platform, a cloud-based 3D genomics tool, supports pharmaceutical and biotech partners.
What could go wrong? The scale of the raise is striking against the pre-placing base: total issued capital will reach 13,440,910,967 shares after admission, a sharp dilution for existing holders. The company has not disclosed how it will use the proceeds.
The signal: Insider participation from the chief executive officer, chairman, and largest backer signals internal conviction, but the heavy share issuance underscores how much fresh capital small AIM-listed biotechs need to fund diagnostics pipelines and platform partnerships.
Read more: kalkinemedia.com
Image credit: USDAgov
